Literature DB >> 26443680

[Current aspects on the management of normal tension glaucoma].

M Töteberg-Harms1, A Rosentreter2, A Lappas3, J Funk1, T S Dietlein4.   

Abstract

In a considerable proportion of glaucoma patients (25-50 %) the intraocular pressure (IOP) is not elevated higher than 22 mmHg at first diagnosis and during subsequent follow-up controls. Although the IOP level remains in the low range < 22 mmHg, progression of glaucoma can still occur. A multitude of different factors are assumed to be involved in glaucoma progression, such as very low nocturnal diastolic blood pressure values, a low mean ocular perfusion pressure, extensive fluctuations in perfusion (e.g. in cases of vascular dysregulation), an increased vulnerability of the optic nerve support structures, an increased translaminar pressure gradient and various underlying systemic diseases. The most important evidence-based aspect of treatment in normal tension glaucoma is pharmaceutical or surgical reduction of the IOP by 30 % or more in comparison to the initial pressure level. Vascular and neuroprotective concepts of treatment for normal tension glaucoma have been strongly advocated and the object of experimental and clinical studies. As yet a clear clinical benefit has not been proven by large prospective randomized studies.

Entities:  

Keywords:  Glaucoma surgery; Intraocular pressure; Ocular perfusion; Risk factors; Therapy

Mesh:

Substances:

Year:  2015        PMID: 26443680     DOI: 10.1007/s00347-015-0140-5

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  62 in total

1.  Natural history of normal-tension glaucoma.

Authors:  D R Anderson; S M Drance; M Schulzer
Journal:  Ophthalmology       Date:  2001-02       Impact factor: 12.079

2.  Ginkgo biloba extract increases ocular blood flow velocity.

Authors:  H S Chung; A Harris; J K Kristinsson; T A Ciulla; C Kagemann; R Ritch
Journal:  J Ocul Pharmacol Ther       Date:  1999-06       Impact factor: 2.671

Review 3.  Role of nocturnal arterial hypotension in the development of ocular manifestations of systemic arterial hypertension.

Authors:  S S Hayreh
Journal:  Curr Opin Ophthalmol       Date:  1999-12       Impact factor: 3.761

4.  Factors that predict the benefit of lowering intraocular pressure in normal tension glaucoma.

Authors:  Douglas R Anderson; Stephen M Drance; Michael Schulzer
Journal:  Am J Ophthalmol       Date:  2003-11       Impact factor: 5.258

5.  Effect of Ginkgo biloba extract on preexisting visual field damage in normal tension glaucoma.

Authors:  Luciano Quaranta; Sabina Bettelli; Maurizio G Uva; Francesco Semeraro; Raffaele Turano; Enrico Gandolfo
Journal:  Ophthalmology       Date:  2003-02       Impact factor: 12.079

6.  Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group.

Authors: 
Journal:  Am J Ophthalmol       Date:  1998-10       Impact factor: 5.258

7.  The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group.

Authors: 
Journal:  Am J Ophthalmol       Date:  1998-10       Impact factor: 5.258

8.  Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey.

Authors:  A Sommer; J M Tielsch; J Katz; H A Quigley; J D Gottsch; J Javitt; K Singh
Journal:  Arch Ophthalmol       Date:  1991-08

9.  Central and paracentral corneal pachymetry in patients with normal tension glaucoma and ocular hypertension.

Authors:  Jens F Jordan; Silke Joergens; Sven Dinslage; Thomas S Dietlein; Günter K Krieglstein
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-08-02       Impact factor: 3.535

10.  Brimonidine prevents neurodegeneration in a mouse model of normal tension glaucoma.

Authors:  K Semba; K Namekata; A Kimura; C Harada; Y Mitamura; T Harada
Journal:  Cell Death Dis       Date:  2014-07-17       Impact factor: 8.469

View more
  2 in total

1.  MicroPulse Transscleral Laser Therapy Demonstrates Similar Efficacy with a Superior and More Favorable Safety Profile Compared to Continuous-Wave Transscleral Cyclophotocoagulation.

Authors:  Enrico Bernardi; Marc Töteberg-Harms
Journal:  J Ophthalmol       Date:  2022-02-08       Impact factor: 1.909

2.  First and second transscleral cyclophotocoagulation treatments provide similar intraocular pressure-lowering efficacy in patients with refractory glaucoma.

Authors:  Enrico Bernardi; Marc Töteberg-Harms
Journal:  Int Ophthalmol       Date:  2022-02-03       Impact factor: 2.029

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.